
Receiving four or less cycles of therapy predicts poor survival in newly diagnosed transplant ineligible patients with myeloma who are treated with bortezomib-based induction
Mollee, Peter, Boyle, Stephen, Wellard, Cameron, Moore, Elizabeth, Blacklock, Hilary, Harrison, Simon J., Ho, P. Joy, hocking, jay, McQuilten, Zoe, Quach, Hang, Spearing, Ruth, Wood, Erica, Spencer, AVolume:
19
Journal:
Clinical Lymphoma Myeloma and Leukemia
DOI:
10.1016/j.clml.2019.09.388
Date:
October, 2019
Fichier:
PDF, 84 KB
2019